Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 61Lymphoma, Follicular 16Recurrence 13Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Acute 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Erythroblastic, Acute 3Leukemia 3

Interventions

Gemcitabine 8Fluorouracil 5Cisplatin 5Leucovorin 4Oxaliplatin 3becatecarin 2Capecitabine 2seribantumab 1sargramostim 1pembrolizumab 1pazopanib 1motexafin lutetium 1ixabepilone 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1durvalumab 1devimistat 1cediranib 1Trastuzumab 1Sorafenib 1Radiosurgery 1Psychiatric Rehabilitation 1Palonosetron 1Observation 1Liver Transplantation 1Folfox protocol 1Escitalopram 1Erlotinib Hydrochloride 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gallbladder Neoplasms × Bortezomib × Clear all
NCT00085410 2017-07-02

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 13 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡